. The flavivirus E protein has approximately 500 amino acids with six conserved disulfide bonds to maintain its conformational structure (20, 29) . The E protein structures have been determined for the tick-borne encephalitis (TBE) virus by using X-ray crystallography (24) and recently have been used for a low-resolution map of whole dengue virions (13). The E protein is a head-to-tail homodimer with three structurally distinct domains: a central ␤-barrel (domain I), an elongated dimerization region (domain II), and a C-terminal immunoglobulin (Ig)-like module (domain III) (24). The E protein is associated with viral attachment, fusion, hemagglutination, cellular tropism, viral virulence, and the induction of protective immune response (17).
Japanese encephalitis virus (JEV) (family Flaviviridae, genus
Flavivirus) is a single-stranded, positive-sense RNA virus with a genome size of approximately 11 kb. The genome contains a single open reading frame encoding three structural proteins (capsid [C] , premembrane [prM/M], and envelope [E] ) and seven nonstructural proteins, and two nontranslating regions flank the 5Ј and 3Ј ends (17, 23, 25) . The flavivirus E protein has approximately 500 amino acids with six conserved disulfide bonds to maintain its conformational structure (20, 29) . The E protein structures have been determined for the tick-borne encephalitis (TBE) virus by using X-ray crystallography (24) and recently have been used for a low-resolution map of whole dengue virions (13) . The E protein is a head-to-tail homodimer with three structurally distinct domains: a central ␤-barrel (domain I), an elongated dimerization region (domain II), and a C-terminal immunoglobulin (Ig)-like module (domain III) (24) . The E protein is associated with viral attachment, fusion, hemagglutination, cellular tropism, viral virulence, and the induction of protective immune response (17) .
The domain III protein contains one disulfide bond to maintain its conformational structure and can be independently folded as a trypsin-resistant core protein (16, 20, 29) . Neutralizing epitopes on the lateral surface of domain III have been identified, including residues 333 (1), 373 to 399 (28) , and 306, 331, and 387 of JEV (30) ; 308, 310, and 311 of louping ill virus (8) ; 384 and 386 of TBE (6, 7) ; 305 of yellow fever virus (27) ; and 383 to 389 (5), 333 to 351 (26) , and 307 (15) of the dengue viruses. However, most studies have not provided detailed molecular information about the spatial configuration of the epitopes on domain III of the flavivirus E proteins, where the epitopes are defined as a few contact residues that are energetically important for binding affinity in the antibody-antigen complex (9, 21) . In this study, domain III of the JEV E protein was expressed in Escherichia coli to investigate the functional epitope determinants for a JEV-specific neutralizing monoclonal antibody (MAb), E3.3 (30) . The alteration of proteins with single or double site-directed mutagenesis was conducted at positions 306 (Glu3Gly), 331 (Ser3Arg), and 387 (Met3Arg). Also, mutations at or near position 331 of the JEV E protein were replaced with alanine or other hydrophobic and charged amino acids. By using complementary structural modeling (4, 14, 22) , the structure of the domain III MAb E3.3 complex was constructed. Specific interactions of the functional epitope determinants on domain III were confirmed by further mutating the combining sites of MAb E3.3 Fab antibody fragment. This study elucidates the detailed molecular structures of the neutralizing epitope determinants on the JEV domain III protein, which can provide useful information for designing new vaccines.
MATERIALS AND METHODS
Virus, cells, and media. The JEV attenuated variant CH2195LA was plaque purified in Vero cells from a Taiwanese isolate (30) and was propagated in Vero cells by using M199 medium (Invitrogen) containing 10% fetal bovine serum (FBS) (Invitrogen). MAb E3.3-producing hybridoma cells were grown in Iscove's modified Dulbecco's medium (Invitrogen) with 10% FBS.
Cloning, expression, purification, and site-directed mutagenesis of E and domain III fusion protein. Viral RNAs were extracted from the culture supernatants of infected Vero cells by using a TRIzol kit (Invitrogen), and the reverse transcriptase-PCR (RT-PCR) was conducted by use of Superscript II RT and Elongase mix enzymes (Invitrogen) to obtain JEV E gene fragments. Oligonucleotide primers used included (i) the full-length E gene with the forward primer 5Ј-ATGC GCGGATCCTTCAACTGTCTGGGAAT-3Ј and the reverse primer 5Ј-GGGGA AGCTTAGCATGCACATTGGTGG-3Ј, (ii) the domain I and II protein gene (residues 1 to 291) with the forward primer 5Ј-ATGCGCGGATCCTTCAACTGT CTGGGAAT-3Ј and the reverse primer 5Ј-GGGGAAGCTTCATTTTTAGCCTG CATTTCAG-3Ј, and (iii) the domain III protein gene (residues 292 to 402) with the forward primer 5Ј-ATGCGCGGATCCGACAAACTGGCCCTGAA-3Ј and the reverse primer 5Ј-GGGGAAGCTTCGTGCTTCCAGCTTTGTGCC-3Ј. The BamHI-HindIII restriction sites are underlined. Site-directed mutagenesis was conducted by using paired complementary oligonucleotides for the desired point mutations to generate specific mutations into the JEV domain III protein. The correct sequence of each mutant of domain III fusion protein constructs was confirmed by DNA sequence analysis. All of these forward primers contained a BamHI restriction site, and the reverse primers contained a HindIII restriction site. Each RT-PCR product was digested with BamHI and HindIII and then was ligated into the BamHI/ HindIII sites of the pET32a vector (Novagen) and expressed as a thioredoxin (Trx) fusion protein. The E. coli strain BL21(DE3) with the pET32a plasmid containing the E gene fragment was cultured overnight and induced by the addition of 1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG) at 25°C for 4 h. Bacteria cells were harvested by centrifugation for sonication, and the expressed proteins were purified by using the Ni-nitrilotriacetic acid agarose column (Qiagen). The eluted recombinant fusion protein was further dialyzed, and the protein concentration was determined by using the Bio-Rad protein assay reagent. phoresis (SDS-PAGE) sample buffer without 2-mercaptoethanol and were boiled for 10 min. Proteins were resolved on SDS-12% PAGE gels and were electrophoretically transferred to nitrocellulose papers. The resultant blots were blocked with 5% skim milk and then were reacted with appropriately diluted MAb E3.3 for a 1-h incubation. The blots were then washed with Tris-buffered saline (TBS) three times and were overlaid with a 1/1,000 dilution of rabbit anti-mouse IgG antibodies conjugated with alkaline phosphatase (KPL). Following another 1-h incubation at room temperature, the blots were developed with 5Ј-bromo-4-chloro-3-indolyl phosphate nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3-indolylphosphate (BCIP) (Invitrogen). ELISA affinity assay. The wells of a 96-well microtiter plate were coated with 100 l of diluted rabbit anti-Trx antibodies (Sigma) and were incubated overnight at 4°C. Following each incubation and subsequent layer of the enzymelinked immunosorbent assay (ELISA), the wells were washed three times with TBS containing 0.05% Tween 20 (TBST). After being blocked by incubation with 5% skim milk in TBST for 2 h at room temperature (200 l per well), 100 l of wild-type or mutant recombinant domain III fusion proteins (10 g/ml) was captured onto rabbit anti-Trx-coated wells for 2 h of incubation. Following this, serial dilutions of purified MAb E3.3 were added and incubated at room temperature for 1 h. The bound antibodies were detected after incubation with the anti-mouse IgG conjugated to peroxidase (KPL) for 1 h at room temperature. The ELISA products were developed by using a chromogen solution containing 2,2⌵-azinobis(3-ethylbenzthiazolinesulfonic acid) (ABTS) and hydrogen peroxide and then were measured at A 405 . The steady-state equilibrium affinity constant, K d , was estimated from the concentration of MAb E3.3 corresponding to 50% maximal binding.
SDS-PAGE and
Recombinant Fab antibody. The cDNA genes of the Fab region of MAb E3.3 were amplified by use of a 3Ј primer of heavy-chain IgG2a Fd (5Ј-GTTCTGA CTAGTATGATGATGATGATGATGGGGCCCTCTGGGCTCAATTTTCT TGTC-3Ј) and the light-chain 3Ј primer (5Ј-GCGCCGTCTAGAATTAACA CTCATTCCTGTTGAA-3Ј). Nine 5Ј primers for Fd and seven 5Ј primers for were paired with the above-described 3Ј primers in order to test for the ability to amplify the variable-region genes of light and heavy chains of MAb E3.3 (11) . The 3Ј primer of heavy-chain IgG2a Fd mentioned above contained extra nucleotides encoding six-histidine residues. The resultant PCR products of heavychain Fd and light-chain genes were digested with XhoI/SpeI and SacI/XbaI, respectively, and then were cloned into XhoI/SpeI and SacI/XbaI sites of the phagemid expression vector pComb3H (provided by Scripps Research Institute, La Jolla, Calif.). The ligation product was transformed into the competent E. coli XL-1 Blue cells (Stratagene). The pComb3H vectors containing the cDNAs of heavy-and light-chain variable regions were digested with SpeI and NheI to remove the gene III fragment for producing the soluble recombinant Fab, after which the resulting vectors were transformed into E. coli XL-1 Blue cells. Bacteria from the transformed colonies were cultured and induced by the addition of 1 mM IPTG. The recombinant Fab were obtained from the periplasm by using six consecutive freeze-thawing steps and were purified through a Ni-nitrilotriacetic acid agarose column and were dialyzed against phosphate-buffered saline.
Antibody modeling and antigen-antibody complex prediction. Fig. 1 (30) . In this study, we further characterized the neutralizing epitope determinants by expressing different E protein fragments in E. coli. Total protein lysates were prepared from the recombinant E. coli and were analyzed in SDS-PAGE. Western blotting of these expressed proteins demonstrated that a 75-kDa band for the full-length E fusion protein and a 32-kDa band for the domain III fusion protein specifically reacted with MAb E3.3 (Fig. 2,  lanes 2 and 4) . No reactivity was found for the domain I and II fusion protein in the Western blot (Fig. 2, lane 3) .
On the basis of the three-dimensional structure of TBE E protein (24), the structural model of JEV E protein ( Fig. 1) indicates that the ABED sheets of domain III contact both the domain I and the cd-loop of domain II. It is thus possible that other residues within the domain I and II region can participate in the binding of MAb E3.3 to domain III. However, according to the structure model shown in Fig. 1 , the residues at 306, 331, and 387 are all located in the loops of AAx, BCx, and FG. The neutralizing epitope of MAb E3.3 are located only on the outer lateral surface of domain III, where the three amino acids at 306, 331, and 387 are located.
Single and double site mutations on the domain III protein. Site-directed mutagenesis was further performed by generating mutant proteins of domain III with single or double mutations at positions 306 (E3G), 331 (S3R), and 387 (M3R). Six clones were obtained to express the mutant domain III fusion proteins (E306G, S331R, M387R, E306G/S331R, E306G/ M387R, and S331R/M387R). Immunoblots of these mutant proteins reacted with MAb E3.3, which shows that S331R, S331R/M387R, and E306G/S331R mutants lost their binding to MAb E3.3 (Fig. 3, lanes 4, 6, and 8) . In contrast, the single site mutations of E306G and M387R and the double site mutation of E306G/M387R retained their binding activities with MAb E3.3 (Fig. 3, lanes 3, 5, and 7) . The negative results with some of the mutations at residue 331 can be interpreted as identifying key amino acids, if these mutations do not affect the overall folding and structure of domain III, to constitute the neutralizing epitope for MAb E3.3.
Alanine mutations at or near position 331 of domain III.
Subsequent mutations at or near position 331 of the E protein were further performed to determine the effects of the amino acid side chains on MAb E3.3 binding. The residues at Ser329, Ser331, and Asp332 were replaced with alanine (i.e., S329A, S331A, and D332A). Mutations on Gly330 and Gly333 were not conducted due to the lack of a side chain of Gly. The binding affinities of each mutant protein to MAb E3.3 were determined by using ELISA (Fig. 4) . Compared with the binding affinity measured on wild-type domain III, D332A has the greatest decrease in the binding affinity for MAb E3.3. S331A exhibits a slightly decreased affinity and S329A gives an insignificant affinity change to MAb E3.3 (Fig. 4A, Table 1 ). Side chain removal of Ser329, Ser331, and Asp332 with Ala resulted in reducing the binding affinities to MAb E3.3, ranking as D332A (25.6-fold decrease) Ͼ S331A (1.6-fold decrease) Ͼ S329A (1.1-fold decrease). Therefore, the negatively charged side chain of Asp332 is also involved in constituting the functional epitope for MAb E3.3.
Amino acid replacements at position 331 of domain III. Further analysis was carried out to determine whether substitution of Ser331 by other amino acids had any effect on the binding of domain III to MAb E3.3. Five mutant domain III fusion proteins that exhibited Ser331 replaced by the glutamic acid (E, negatively charged), arginine (R, positively charged), lysine (K, positively charged), leucine (L, hydrophobic), and glutamine (Q, neutral polar) were constructed. Positively and negatively charged mutations of S331E, S331K, and S331R decreased the binding affinities by more than 100-fold (Fig. 4B, Table 1 ), suggesting that the interposition of a negative or positive charge at position 331 is important. Since a negative or positive charge at position 331 is close to the functional residue Asp (D) at 332, it is possible that the repulsion or attraction of the charged groups between residues 331 and 332 influence the conformation of antigen-antibody recognition as previously reported (18) . In contrast, hydrophobic and neutral polar mutations of S331L and S331Q only decreased the binding affinities by 1.1-fold (Fig. 4B , Table 1 ), suggesting that either a large polar glutaminyl group or a long hydrophobic aliphatic side chain at position 331 has no significant effect for MAb E3.3 binding.
Amino acid replacements at position 332 of domain III. Five altered proteins at Asp332 were also obtained by using replacements with the same residues (D332E, D332K, D332R, D332Q, and D332L). The mutants of D332K (positively charged), D332R (positively charged), and D332L (hydrophobic) yielded binding affinities decreased by more than 100-fold. However, D332Q (neutral polar) and D332E (negatively charged) mutant proteins resulted in a 16-and 9-fold reduction in their binding affinities to MAb E3.3, respectively (Fig. 4C , Table 1 ). The order of the reduced affinity of Asp332-substituted mutants was D332K (Ͼ100-fold), D332R (Ͼ100-fold), D332L (Ͼ100-fold), D332Q (15.8-fold), and D332E (9.1-fold) (Fig. 4C, Table 1 ). These results indicated that the change from negative-to positive-charge residues (D332K, D332R) was the most significant factor for the domain III-MAb E3.3 interaction. However, the change to another negatively charged residue (D332E) was less significant. An explanation for this observation is that the negative charge of Glu at posi- tion 332 might involve salt bridges and hydrogen bonds with MAb E3.3. In contrast, the change to a large hydrophobic side chain (D332L) was more significant than that to a polar amide group (D332Q), suggesting that a hydrogen bond formation occurs in the interactions between domain III and the combining sites of MAb E3.3.
Computer modeling of the interactions among positions 331 and 332 of domain III with the combining sites of MAb E3.3. For constructing the structural model of MAb E3.3 bound with domain III, the light-and heavy-chain variable-region sequences of MAb E3.3 were sequenced from the E3.3 Fabproducing bacterial clone. The initial structural model of the domain III-MAb E3.3 complex was constructed by docking Ser331 and Asp332 on domain III to fit in the combining sites of MAb E3.3 and then was optimized by using an energy minimization and molecular dynamic. The structural model of the domain III-MAb E3.3 complex (Fig. 5) (Fig. 6) . However, the mutant E3.3 Fab-R94E combined with the D332R mutant (double mutant combination) reveals a substantial restoration of the binding ability for E3.3 Fab-R94E and wild-type domain III (Fig. 6 ). This implies that Asp332 on domain III forms a salt bridge pair with Arg H94 in MAb E3.3.
The critical role of Arg H94 in MAb E3.3 was ascertained according to fact that the double mutant combination (E3.3 Fab-R94E and D332R mutants) restored the binding interaction in the domain III-E3.3 Fab complex (Fig. 6 ). Our finding was contrary to that of a previous report that Arg H94 at the base of CDR H3 usually has hydrogen bonding with Asp H101 
